Views 36
Citations 0
March 21, 2012

Response to Etanercept in Juvenile Idiopathic Arthritis—Reply

Author Affiliations

Author Affiliations: Department of Pediatrics/Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, the Netherlands (

JAMA. 2012;307(11):1140-1141. doi:10.1001/jama.2012.329

In Reply: Dr Pang and colleagues bring up the importance of the differences in etiology and pathogenesis between systemic JIA compared with other JIA categories. As more insight into the pathogenesis of systemic JIA has been gained, systemic JIA has been considered by many as a different disease entity because of its clinical features and the involvement of different cytokines, such as interleukin 1 (IL-1), IL-6, and IL-18, in addition to tumor necrosis factor (TNF). While newer biological agents targeting the IL-1 and IL-6 cytokines seem important for systemic JIA, since 1999 many patients with systemic JIA have been treated successfully with etanercept, a TNF antagonist, in daily clinical care.1

First Page Preview View Large
First page PDF preview
First page PDF preview